Document:

<PAGE>
                                                                   EXHIBIT 10.17

Portions of the following exhibit have been omitted under a request for
confidential treatment under Section 24b-2 of the Securities Act of 1934.
Locations of these omitted portions is denoted by the following legend. [ * * ]

                                LICENSE AGREEMENT

         THIS LICENSE AGREEMENT ("Agreement") is made this 3rd day of October,
2001, by and between Ash Medical Systems, Inc. ("AMS"), an Indiana corporation
having a principal place of business at 2700 Kent Avenue, West Lafayette,
Indiana, and Rockwell Medical Technologies, Inc. ("RMTI"), a Michigan
corporation having a principal place of at 30142 Wixom Road, Wixom, Michigan.

                                   WITNESSETH:

         WHEREAS, AMS represents and warrants that it is the owner of certain
proprietary technology, a patent granted, U.S. and foreign patent applications
pending, processes, methods, designs, technical know-how, information,
associated rights and tangible property relating to a Iron Delivery Method for
transferring iron to a patient from dialysate more specifically set forth in
U.S. Patent No. 5,906,978, European Patent Application No. 97937224.05, Canadian
Patent Application No. 2,263,779, and U.S. Continuation Patent Application
Serial No. 09/143,143 (the "Technology"); and

         WHEREAS, RMTI desires to secure from AMS, and AMS is willing to provide
RMTI with an exclusive, worldwide, non-transferable license to use the
Technology to manufacture, have manufactured, use, commercialize and sell liquid
and/or dry dialysate compositions which utilize the Technology for the treatment
of patients in renal failure by hemodialysis or peritoneal dialysis (or by any
therapy) (hereinafter referred to as the "Products") upon certain terms and
conditions.

         NOW THEREFORE, for and in consideration of the recitals and covenants
set forth herein, the parties agree as follows:

                                    ARTICLE I
                                      TERM

          This Agreement shall begin on the date first written above and shall
 continue until terminated by agreement of the parties or as otherwise provided
 herein. Each subsequent twelve (12) month period constitutes a year ("Year").

                                                                    Page 1 of 10
<PAGE>

                                   ARTICLE II
                                GRANT OF LICENSE

        AMS hereby grants to RMTI, subject to the conditions outlined in
Article III, an exclusive, worldwide, non-transferable license to manufacture,
have manufactured, commercialize, use, market, and sell the Products, and/or
otherwise exploit the Technology in the treatment of patients with renal failure
by hemodialysis and peritoneal dialysis, such Technology relating to the
delivery of iron from dialysate includes all inventions, improvements,
enhancements and modifications thereto made, conceived or acquired by AMS after
the date of this Agreement and any patent based on and covering the same which
AMS now or thereafter owns, controls or has the right to commercially exploit.

                                   ARTICLE III
                             CONSIDERATION FOR GRANT

         3.1 Patent Costs. If RMTI deems it necessary for AMS to seek additional
patent protection on any portion of the Technology not already covered by U.S.
Patent No. 5,906,978 and pending U.S. and foreign patent applications to enhance
protection of their exclusive license, AMS, at RMTI's expense, will prepare and
file the requested patent applications. All future costs for filing,
prosecuting, issuing, and/or maintaining patents covering the Technology,
including the existing patents and patent technology and such additional patent
applications requested by RMTI, including maintenance fees once patent(s) issue,
will be borne by RMTI as long as this Agreement is in force. All future costs
for filing, prosecuting, issuing, and/or maintaining corresponding foreign
patents shall be borne by RMTI during the term of the Agreement. RMTI agrees to
pay all outstanding invoices for filing, prosecuting, issuing, and/or
maintaining patents associated with the Technology existing at the time of
execution of this Agreement, in a total amount not to exceed Ten Thousand
Dollars ($10,000.00). AMS will use best efforts to keep RMTI fully advised as to
the status and course of prosecution of all such pending patent applications,
including supplying copies of all official papers received, and copies of all
papers filed by the attorneys involved. Upon 15 days advance notice to AMS, RMTI
has the right to discontinue preparation and/or prosecution of any such
additional patent(s) at any time, and shall be kept advised of the status of
same in a manner sufficiently detailed and prompt to enable effective exercise
of this right. AMS shall have the right to continue

                                                                    Page 2 of 10
<PAGE>

efforts to obtain any such existing or additional patents at its own expense in
any instance where RMTI decides to discontinue such efforts.

         3.2 Non-Refundable License Fee. RMTI agrees to pay AMS the sum of Two
Hundred Fifty Thousand Dollars ($250,000.00) license fee, which shall be
non-refundable, payable in three segments: One Hundred Thousand Dollars
($100,000.00) upon execution of this Agreement; Seventy-Five Thousand Dollars
($75,000.00) within six (6) months of such date; and Seventy-Five Thousand
Dollars ($75,000.00) within twelve (12) months of such date.

         3.3 Royalty. RMTI shall pay AMS a royalty ("Royalty") in the amount of
[* *] of RMTI's increase in revenue over the revenue that RMTI would have earned
on its liquid and dry dialysate without the Product. The Royalty will be based
on [* *] of the increase in the "average actual selling price" over the "base
average actual selling price" of liquid and dry dialysate containing the
Product, on a 55-gallon drum equivalent basis. The "average actual selling
price" of the Product includes actual gross invoice price for Products sold to
independent and unrelated third parties in the normal course of business, less
any and all chargebacks, rebates, discounts, buying group discounts, taxes,
duties, handling or other charges, credits, fees allowances, and returns. The
"base average actual selling price" is the weighted average actual selling price
of liquid and dry dialysate products without iron on a 55-gallon drum equivalent
basis sold by RMTI during the 12-month period preceding the month in which RMTI
first offered Products for sale. The "base average actual selling price" will be
readjusted, using a 12 month weighted average, every anniversary date from the
date the Product was first offered for sale, however, it can never be adjusted
lower than the initial 12-month period preceding the month in which RMTI first
offered Products for sale. Royalty shall be paid on the 15th day of the second
month following the month in which the Royalty was earned.

         3.4 Continuation Fee. In the event that RMTI does not have the Product
to the market by the end of Year 5 of this Agreement, RMTI shall have the choice
to pay AMS the additional sum of $250,000.00 per annum as a fee for continuation
of this Agreement ("Continuation Fee") until the Product is on the market. Once
the Product is on the market the Continuation Fee will be eliminated.
Continuation Fees, if due, will be paid on anniversary date of this Agreement
beginning with the 5th anniversary date.

                                                                    Page 3 of 10
<PAGE>

         3.5 Technical Support. RMTI, at its sole cost and expense, shall be
responsible for all regulatory affairs associated with the Products, including
clinical trials and commercialization submissions to the U. S. Food and Drug
Administration. AMS, including its Medical Director, agrees to provide, and RMTI
agrees to pay AMS for, such reasonable technical and clinical support as RMTI
may request. AMS' current Medical Director, Dr. Stephen R. Ash, shall be billed
at the rate of $187.50 per hour or $1,500.00 per day and all other personnel
will be billed at mutually agreed-upon market rates. Expenses will be reimbursed
promptly upon invoicing by AMS.

         3.6 Audits. RMTI shall make its records and facilities involved in the
performance of this Agreement available to independent CPA auditors designated
by and at the expense of AMS, at reasonable and mutually convenient times during
normal business hours for audit purposes and shall take any reasonable actions
facilitate such. All information obtained during any such audit shall be deemed
confidential, and such auditors shall report to both AMS and RMTI only the
conclusion reached by their audit relative to the accuracy and adequacy of
Royalty payments made to AMS hereunder

                                   ARTICLE IV
                 WARRANTIES AND REPRESENTATIONS BY AMS AND RMTI

         4.1 AMS warrants to RMTI that AMS is the sole and exclusive owner of
the Technology as of the date of execution hereof, including all patents and
patent applications, that AMS has the right to grant the exclusive license
granted hereunder; that no agreement or other document effective as of the date
of execution hereof has been executed which is in conflict herewith and will not
execute any such agreement during the term hereof; that AMS officers have the
full right, authority and authorization to execute this Agreement and to grant
the exclusive rights granted to RMTI hereunder; and that no consent or
authorization of any third party is required as a condition precedent to its
execution or performance of this Agreement.

         4.2 RMTI hereby represents to AMS that it has executed no agreement or
other document in conflict herewith; that its officers have the full right,
authority and authorization to execute this Agreement; and that no consent or
authorization of any third party is required as a condition precedent to its
execution or performance of this Agreement.

                                                                    Page 4 of 10
<PAGE>

         4.3 RMTI represents to AMS that no Products will be knowingly sold or
otherwise distributed except in full compliance with all legal and regulatory
requirements.

                                    ARTICLE V
               INFORMATION AND OWNERSHIP REGARDING THE INVENTIONS

         5.1 The Technology which relates to the delivery of iron by dialysate,
and all inventions, improvements, enhancements and modifications thereto made,
conceived or developed by AMS or its agents or representatives after the date of
this Agreement, and any patent covering the same in whole or in part which AMS
now or hereafter owns, controls or has the right to commercially exploit, shall
be and remain the sole and exclusive property of AMS, subject to and included
within the license hereby granted. AMS shall, upon demand, execute and deliver
to RMTI, or cause to be executed and delivered to RMTI, such documents as may be
deemed necessary or advisable by counsel for RMTI for filing in the appropriate
public offices to evidence the grant of the exclusive license hereby granted to
RMTI.
         5.2 All inventions, improvements, enhancements and modifications to the
Technology made, conceived or developed by RMTI or its agent and representative
during the term of this Agreement and any patent covering the same in whole or
in part ("RMTI Enhancements"), shall be the sole property of RMTI. Should RMTI
chose not to maintain its exclusive license under Section 3.4 of this Agreement,
or if this Agreement is terminated by AMS or RMTI under Section 7 of this
Agreement, RMTI grants AMS a non-exclusive, royalty-free license to exploit such
RMTI Enhancements.

                                   ARTICLE VI
                   INFRINGEMENT, INDEMNIFICATION AND INSURANCE

         6.1 Infringement. RMTI may choose to prosecute at its own expense and
for its own benefit, any party infringing on the rights granted to RMTI pursuant
to this Agreement and AMS shall cooperate fully with such. In any case where
RMTI chooses not to prosecute an infringing party, AMS shall have the right to
prosecute at its own expense and for its own benefit such infringing party and
RMTI shall cooperate fully with such.

                                                                    Page 5 of 10
<PAGE>
         6.2      Indemnification.

                           6.2.1 RMTI shall indemnify and hold harmless AMS, its
                  officers, directors, agents and representatives, and employees
                  from and against any and all claims, losses, damages,
                  judgments, costs, awards, expenses (including reasonable
                  attorney's fees) and liabilities of every kind (collectively,
                  "Losses") arising directly out of or resulting directly from
                  any breach by RMTI of any of its warranties, guarantees,
                  representations, obligations or covenants contained herein.

                           6.2.2 AMS shall indemnify and hold harmless RMTI, its
                  officers, directors, agents and representatives, and employees
                  from and against any and all Losses arising directly out of or
                  resulting directly from any breach by AMS of any of its
                  warranties, representations, obligations or covenants
                  contained herein.

         6.3      Insurance. RMTI agrees to purchase, at its sole cost,
comprehensive general liability insurance (occurrence or claims-made form) for
bodily injury and property damage, including contractual and product liability,
in an amount of not less than $3,000,000 combined single limits and provide AMS
with a certificate of insurance naming AMS as an additional insured. Such
contract of insurance shall be primary with respect of any other insurance
available to AMS and shall contain a waiver of subrogation by RMTI's insurance
carrier against AMS and its insurance carrier with respect to all obligations
assumed by RMTI pursuant to this Agreement. Such insurance shall contain
provisions to the effect that policy limits may not be reduced, terms changed,
or the policy canceled with less than thirty (30) days written notice to AMS.

         6.4      Sublicenses. It is recognized that RMTI may from time to time
deem it necessary or desirable to grant sublicenses to third parties under the
Technology licensed to it pursuant to this Agreement, under terms and conditions
it deems best suited to each such situation, in order to prevent unlicensed
infringement, resolve disputes and/or litigation, maintain orderly and effective
marketing of the Products or for other reasons, and the parties therefore agree
that in any such event RMTI will first consult with AMS concerning each such
matter and AMS shall have the right to approve or disapprove any such
sublicense, providing however that AMS shall not act unreasonably in exercising
such right. RMTI agrees to preserve AMS' royalty dollar amount on a 55-gallon
drum equivalent basis if Products are sublicensed.

                                                                    Page 6 of 10
<PAGE>

                                   ARTICLE VII
                                   TERMINATION

         7.1 This Agreement may be terminated as follows:

                           7.1.3 At the sole option of AMS and upon written
             notice by AMS, in the event RMTI fails to meet any of its financial
             obligations under this Agreement. RMTI will have fifteen (15) days
             following receipt of notice to cure the violation.

                           7.1.2 At the option of either party and upon thirty
             (30) days written notice, in the event of the other party's failure
             to perform any of its non-financial duties or obligations under
             this Agreement. The defaulting party will have thirty (30) days
             following receipt of notice to cure the violation.

                           7.1.3 At the option of RMTI, at any time during the
             term hereof upon ninety (90) days written notice.

         7.2 Remedies hereunder are not exclusive. The non-breaching party shall
have all remedies available at law or in equity. The provisions of Article VIII
and the obligations for payment of royalties under Section 3.3 shall survive any
termination of this Agreement.

                                  ARTICLE VIII
                                 CONFIDENTIALITY

         8.1 Definition of Confidential Information. As used in this Agreement,
"Confidential Information" shall mean all information which is transmitted in
written, graphic or photographic form and marked as "Confidential" or if
transmitted in oral form and reasonably known to be confidential or claimed to
be so by the discloser at the time of transmittal, but Confidential Information
does not include that which (a) can be shown by the receiving party to have been
in its possession prior to disclosure to it by the transmitting party; (b) at
the time of disclosure hereunder is, or thereafter becomes, through no fault of
the receiving party, part of the public domain by publication or otherwise; or
(c) is furnished to the receiving party by a third party after the time of
disclosure hereunder as a matter of right, who owes no obligation of
confidentiality to the transmitting party with respect to the Confidential
Information.

         8.2 Exchange of Information. All Confidential Information exchanged
between AMS and RMTI pursuant to this Agreement or previously exchanged between
AMS and

                                                                    Page 7 of 10
<PAGE>
RMTI relating to the subject matter hereof, shall be kept confidential by each
party with the same degree of care normally accorded by such party to its own
confidential information except for purposes authorized by this Agreement.
Neither party shall disclose such Confidential Information to any person or
entity during the term of this Agreement, provided, however, that each party may
disclose said Confidential Information to responsible officers and employees of
any party who require said information for the purposes contemplated by this
Agreement, provided that said officers and employees shall have assumed like
obligations of confidentiality. This obligation of confidentiality shall survive
the termination of this Agreement for a period of five (5) years after the
termination of this Agreement.

                                   ARTICLE IX
                                  ASSIGNABILITY

         9.1 Notwithstanding the references in this Agreement to
non-transferability of the license contained herein, (i) AMS shall be permitted
to assign its rights and obligations under this Agreement to a third party
purchaser of all or substantially all of AMS' business, and (ii) RMTI shall be
permitted to assign its rights and obligations under this Agreement to a third
party purchaser of all or substantially all of RMTI's business. This Agreement
shall be binding upon and shall inure to the benefit of AMS and RMTI and their
permitted assigns and successors in interest.

                                    ARTICLE X
                                  GOVERNING LAW

         10.1 This Agreement shall be governed by and construed in accordance
with the laws of the State of Indiana; provided, however, that any patent
question or controversy shall be resolved in the courts having jurisdiction over
the patent in question in accordance with the laws applicable to such patent.

                                                                    Page 8 of 10
<PAGE>

                                   ARTICLE XI
                                     NOTICES

         11.1 For purposes of notices given pursuant to this Agreement, the
addresses as set forth in Section 11.2 shall be used unless changed by written
notice given by one party to the other:

         11.2 For the purposes of notices under Section 11.1 above, the
following addresses shall be used:

         For AMS:          Ash Medical Systems, Inc.
                           2700 Kent Avenue
                           West Lafayette, IN  47906
                           Attn.:  Robert B. Truitt, President and CEO
                           Facsimile Number:  (317) 463-4129

         For RMTI:         Rockwell Medical Technologies, Inc.
                           30142 Wixom Road
                           Wixom, MI 48393
                           Attn.:  Robert Chioini, Chairman, President, CEO
                           Facsimile Number:  (248) 960-9119

         11.3 All notices hereunder shall be in writing and shall be deemed
given when (a) personally delivered; (b) when received, if mailed by certified
mail, return receipt requested, postage prepaid; (c) when received when sent by
courier service, UPS, or equivalent carrier; or (d) on the first business day
after receipt of facsimile copy when transmitted by confirmed facsimile, with
hard copy mailed by United States mail.

                                   ARTICLE XII
                                  MISCELLANEOUS

         12.1. Headings. The headings used in this Agreement are for purposes of
convenience and ready referral and shall not be deemed to limit the construction
of any paragraph to which they appertain.

         12.2 Severability. The invalidity or unenforceability of any provision
of this Agreement shall not affect or limit the validity or enforceability of
any other provision hereof.

                                                                    Page 9 of 10
<PAGE>

         12.3 No Waiver. No waiver by either party or any breach of the terms of
this Agreement shall be deemed a waiver of any subsequent breach thereof.

         12.4 Entire Understanding. This Agreement embodies the entire
understanding and agreement between the parties and supersedes all previous
negotiations, representations and writings, written or oral, with respect to the
subject matter hereof. This Agreement may be amended or modified only by an
instrument in writing, duly signed by the parties hereto.

         12.5 This Agreement may be executed in more than one counterpart, each
of which shall be deemed an original document, and all of which taken together
shall be one and the same agreement.

ATTEST:                             ASH MEDICAL SYSTEMS, INC.

                                    By: /s/ Robert B. Truitt
---------------------------             ---------------------------
                                        Robert B. Truitt
                                        President and CEO

ATTEST:                             ROCKWELL MEDICAL TECHNOLOGIES, INC.

                                    By: /s/ Robert L. Chioini
---------------------------             ---------------------------
                                            Robert Chioini
                                            Chairman, President, CEO

                                                                   Page 10 of 10<PAGE>
                                                                   EXHIBIT 10.18

Portions of the following exhibit have been omitted under a request for
confidential treatment under Section 24b-2 of the Securities Act of 1934.
Locations of these omitted portions is denoted by the following legend. [ * * ]

                                LICENSE AGREEMENT

THIS LICENSE AGREEMENT ("Agreement") is made this 7th day of January, 2002, by
and between: Dr. Ajay Gupta ("AG"), an individual residing at 18946 Vickie
Avenue, Apt #241, Cerritos, CA 90703, Charak LLC ("CHARAK"), a corporation
organized under the laws of the State of Michigan located at 2336 Hickory Point
Drive, Ann Arbor, Michigan and owned by AG, and Rockwell Medical Technologies,
Inc. ("RMTI"), a corporation organized under the laws of the State of Michigan
located in Wixom, Michigan.

                                   WITNESSETH:

WHEREAS, CHARAK and AG represent and warrant that CHARAK is the owner of certain
proprietary information and technology, including medical and scientific
information, clinical and other information, submissions, and records relating
to FDA approval carried on heretofore, processes, methods, technical know-how
and information attributable to and known by AG personally including
confidential and trade secret information, and associated rights and tangible
property and U.S. and foreign patent applications pending all relating inter
alia to delivery of Iron Salt(s), especially ferric pyrophosphate, and
pharmaceutically acceptable salts thereof delivered through dialysate to
patients suffering from renal failure more specifically set forth in pending
U.S. Patent Application Nos. 08/775,595 (and related Provisional Application No.
60/055,315), and 09/367,629, and related International Patent Applications Nos.
PCT/US98/16383, (WO98US16383), (WO9907419A1) and (WO97US23719) (WO9829434A1)
(International Patent Applications and National State Patent Applications in
foreign countries based on such International Patent Applications (foreign
patent applications)), (all such patent applications and all patents issued
therefrom comprising the "Patent Rights," and all such technology hereinafter
collectively referred to as "CHARAK TECHNOLOGY"), subject only to the rights of
Henry Ford Health Systems Inc., a Michigan Corporation ("HFHS") to use the
Patent Rights and know-how existing as of the date hereof for the sole purpose
of research at its principal research facility or patient use within the
existing HFHS facilities as the same may be expanded in the ordinary course of
business ("the HFHS Shop Right"); and

         WHEREAS, RMTI desires to secure from CHARAK, and CHARAK is willing to
provide RMTI, upon certain terms and conditions, an exclusive, worldwide,
non-transferable license to use the CHARAK TECHNOLOGY (less the HFHS Shop Right)

                                                                    Page 1 of 20
<PAGE>

("the Licensed Technology,") which expression shall include Enhancements (as
herein defined) of CHARAK, AG, and/or CHARAK Affiliates (hereinafter defined)
including a license to manufacture, use, commercialize and sell liquid and/or
dry dialysate compositions which utilize and are protected by the Licensed
Technology ("the Licensed Products").

         NOW THEREFORE, for and in consideration of the recitals and covenants
set forth herein, the parties agree as follows:

                                    ARTICLE I
                                      TERM

The term of this Agreement (the "Term") shall commence on the date first written
above and shall continue on a product by product and Enhancement by Enhancement
and country by country basis until the last patent included in the Patent Rights
covering a Licensed Product or Enhancement in any country in which RMTI remains
licensed hereunder expires, plus a period of ten years. The Term with respect to
any product or Enhancement in any country shall automatically be extended for
successive one (1) year periods unless, at least twelve months before the
expiration of the original or any renewal Term, either party gives written
notice to the other that it does not wish to extend the Agreement with respect
to such product or Enhancement in such country. For purposes of this Article, a
patent included in the Patent Rights covers a Licensed Product (or Enhancement)
if the manufacture, use and/or sale of the Licensed Product or Enhancement
would, absent a license granted hereunder, infringe such patent.

                                   ARTICLE II
                                GRANT OF LICENSE

CHARAK hereby grants to RMTI, subject to the conditions herein including as
outlined in Article III and subject to the HFHS Shop Right, an exclusive,
worldwide, non-transferable license to manufacture, have manufactured,
commercialize, use, market, offer for sale, and sell the Licensed Products,
and/or otherwise exploit the Licensed Technology in the treatment of patients
with renal failure by hemodialysis, peritoneal dialysis or by any other therapy,
together with the right to grant sublicenses for any or all such Licensed
Product(s) and/or Licensed Technology, as set forth more fully hereinafter. The
Licensed

                                                                    Page 2 of 20
<PAGE>

Technology shall include all inventions, improvements, and modifications thereto
("Enhancements") made, conceived or acquired by CHARAK, AG and any CHARAK
Affiliate (as defined more particularly hereinafter) during the term of this
Agreement, and any patent based on and covering the same which CHARAK, AG or any
CHARAK Affiliate now or hereafter owns, controls or has the right to
commercially exploit.

                                   ARTICLE III
                             CONSIDERATION FOR GRANT

         3.1 Patent/Other Obligations and Costs. If RMTI deems it necessary for
CHARAK to obtain additional patent protection on any portion of the Licensed
Technology, whether now existing or developed in the future, not covered by
patents issued from the Patent Rights, to assure protection of their exclusive
license rights herein, CHARAK, at RMTI's expense, will prepare and file the
requested patent applications.

RMTI shall use its best reasonable efforts, on a country by country basis, to
obtain, and thereafter maintain, Foreign Registrations or Approvals to market
the Licensed Products in order to enable their full commercial exploitation,
commensurate with RMTI's size, capabilities, and reasonable business judgment as
to feasibility and return on investment, and will use best efforts to do so
within one year following the date of patent issuance in countries where patent
protection is obtained, but delay by regulatory authorities shall not be deemed
lack of best reasonable effort by RMTI.

After obtaining regulatory approval to market the Licensed Products, RMTI shall
use its best reasonable efforts on a country by country product by product basis
to market the Licensed Products.

All future costs for filing, prosecuting, and/or issuing patent applications
and/or maintaining patents (both existing patent applications and additional
patent applications requested by RMTI) covering either in full or part the
Licensed Technology, including maintenance fees once patent(s) issue, will be
borne by RMTI as long as this Agreement is in force, on a country by country
basis, except as provided below. In addition, RMTI agrees to reimburse AG for
all bona fide, reasonable and documented expenses related to prosecution, filing
and maintenance fees of patent applications within the Patent Rights incurred
prior to the date hereof, but only to the extent such expenses do not duplicate

                                                                    Page 3 of 20
<PAGE>

expenses reimbursed by Shein, and only to the maximum allowable extent of Twenty
Five Thousand Dollars U.S. ($U.S. 25,000).

CHARAK warrants that it will keep RMTI and its designated counsel promptly and
fully advised, at RMTI cost, as to the status and course of prosecution of all
such pending patent applications, including supplying copies of all official
papers received, copies of all papers filed by the attorneys involved and copies
of all correspondence to and from such attorneys regarding such applications.
RMTI shall have the right to make final decisions as to what is done in each
step in the course of prosecution in all such cases so long as it is obligated
to pay the related expenses. In any instance where RMTI decides not to proceed
with or otherwise discontinue prosecution or maintenance of any patent or
application, it shall to the extent reasonably possible notify CHARAK in
sufficient time to permit CHARAK to act and CHARAK may elect to continue on its
own and at its own expense.

         3.2 Conditionally Non-Refundable License Fee. RMTI agrees to pay CHARAK
a license fee, which shall be non-refundable except for CHARAK's breach of
warranty or fraud, payable in 6 segments as follows: Fifty Thousand US Dollars
(US $50,000) at the time of execution of this Agreement, to be paid in the
common stock of RMTI valued at a price per share corresponding to that existing
at the close of trading on the NASDAQ exchange on the previous day; Seventy Five
Thousand U.S. Dollars (U.S. $75,000) upon issuance of a U.S. Patent based on
U.S. Patent Application No. 08/775,595 with claims generally corresponding to
those present in the application prior to the date of execution hereof; Fifty
Thousand US Dollars (US $50,000) upon successful completion of Phase III
clinical trials and filing with the FDA for 510(k) approval; One Hundred
Thousand US Dollars (US $100,000) upon approval of the therapy by the US FDA;
One Hundred Seventy Five Thousand US Dollars (US $175,000) upon successful
assignment of a billing/reimbursement code for the Licensed Products by the
United States Health Care Financing Administration (HCFA); and One Hundred Fifty
Thousand U.S. Dollars (U.S. $150,000) upon the grant of Orphan Drug Status by
the FDA.

3.2.1 In the event of CHARAK or AG's breach of warranty or fraud during the
active term of this Agreement, the license fees received by CHARAK shall be
refundable as follows:

                                                                    Page 4 of 20
<PAGE>

-        Full amount received by CHARAK, if such event occurs during the first
         five years from the date of this Agreement, and
-        Only one-half the amount received by CHARAK, if such event occurs
         later.

     3.3 Royalty. RMTI shall pay Charak a Royalty ("Royalty") based on RMTI's
average actual selling price of Licensed Products, as particularly specified
herein, where the selling price of Licensed Products exceeds [*
                                *], at rates set forth below, and, if the
selling price of Licensed Products is below [*
                 *], RMTI shall pay Charak a Royalty ("Royalty") based on
RMTI's Revenue Advantage, which will be based on RMTI's increase in per unit
revenue, received by RMTI, for liquid and dry dialysate products which embody
Licensed Technology ("Licensed Products") with respect to the per unit revenue
received by RMTI in that country for liquid and dry dialysate products that do
not embody Licensed Technology ("Conventional Products").

The Royalty Rate to be used in calculating Royalty payable to CHARAK for each
country or territory in which Licensed Products are sold by RMTI at per-drum
sales prices of [*                                          *], for sales of
Licensed Products at per-drum prices between [*
                 *] and for per drum sales prices of Licensed Products less than
[*                                      *] of the prevailing RMTI Revenue
Advantage, in countries where the Licensed Products are covered by patents which
have not expired or been invalidated or held unenforceable by a court of
competent jurisdiction, and in countries where the Licensed Products are subject
to a grant of regulatory exclusivity. In all other countries or territories, and
after any or all patents included in Licensed Technology have expired or
regulatory exclusivity has expired, the corresponding Royalty Rates shall be
reduced to [*
                              *].

The Revenue Advantage Royalty will be calculated by using the increase in the
"average actual selling price" of Licensed Products over the "base average
actual selling price" of Conventional Products, on a 55-gallon drum equivalent
basis ("a unit") in each country or territory where Licensed Products are sold.
The "average actual selling price" of the Licensed Products in a given country
is the weighted average actual gross invoice price received by RMTI per unit
sold to independent and unrelated third parties in or for that

                                                                    Page 5 of 20
<PAGE>

country in the normal course of business, less any and all chargebacks, rebates,
discounts, buying group discounts, taxes, duties, handling or other charges,
credits, fees allowances, and returns, on a 55-gallon drum equivalent basis
(i.e., per unit) sold by RMTI during the 12 month period preceding the month in
which RMTI sells Licensed Products during each quarterly period for which a
Royalty is payable. The "base average actual selling price" in a given country
is the weighted average actual selling price of liquid and dry dialysate
products without the Licensed Technology (Conventional Products), on a per unit
basis, sold in that country. If RMTI sells Licensed Products in any new
territory for which it does not already have a "base average actual selling
price" of its Conventional Products, it will initially use the same "base
average actual selling price" as that prevailing in the United States, which
will then be applied to the weighted average actual selling price of Licensed
Products in the territory involved to calculate the "Revenue Advantage".

Royalty to CHARAK for Licensed Product drum prices less than [*             *] =
Royalty Rate x Unit Volume x Revenue Advantage [i.e., Average Actual Selling
Price with Licensed Technology minus Average Actual Selling Price without
Licensed Technology].

If the Licensed Technology is sold separately from RMTI's Conventional Product,
the Licensed Technology will earn a specified royalty. The royalty will be
[*             *] of revenue of the Licensed Technology in all countries,
provided it has exclusivity via a patent or Orphan Drug Designation. If after
any or all patents included in Licensed Technology have expired or regulatory
exclusivity has expired, or there is no exclusivity, the corresponding Royalty
Rate shall be [*             *] in all countries.

The Royalty shall be payable to CHARAK within one month of the quarter most
recently ended and RMTI shall provide duly verified details and computation
basis for computation to CHARAK for CHARAK's verification/audit.

         3.4 Sublicense Rights. CHARAK grants RMTI the right to issue
sublicenses for the Licensed Technology, to the full extent of but not exceeding
the rights of RMTI under this Agreement, or less than that, on particular terms
and conditions deemed best by RMTI in each instance, with appropriate disclosure
of CHARAK's rights. RMTI shall promptly advise CHARAK as to the issuance of each
and every such sublicense, identifying the sub-licensee by name and address,
shall promptly account to CHARAK for all sales of Licensed Products by such
sub-licensees, and shall pay royalties to CHARAK

                                                                    Page 6 of 20
<PAGE>

for such sub-licensee sales within thirty (30) days following the end of each
quarter, on the same overall basis as RMTI is itself obligated to CHARAK for
RMTI's sales under this Agreement, but based on the pricing used by each
Sublicensee in each country or territory.

         3.5 Commercialization and Technical Support. RMTI undertakes and agrees
with CHARAK to faithfully and diligently exploit, on the basis set forth in
paragraph 3.1 hereinabove, the commercial potential of the Licensed Technology.
RMTI, at its sole cost and expense, shall be responsible for all regulatory
affairs associated with the Licensed Products during the active term of this
Agreement in all countries or territories for which this agreement remains in
effect, including clinical trials and commercialization submissions to the U. S.
Food and Drug Administration, but CHARAK and AG shall assign to RMTI all rights
and status obtained prior to the date of this Agreement and shall cooperate and
assist RMTI in all ways and at all times reasonably requested by RMTI. RMTI
shall prepare and submit in its name a completed new drug and/or device
application (NDA) (or the equivalent in other countries) for the Licensed
Product and shall use its best reasonable efforts to obtain FDA approval of the
NDA. RMTI shall be responsible for obtaining applicable State
regulatory/formulary approvals for the marketing, sale and distribution of
Licensed Products in both the U.S. and foreign countries.

Throughout the term of this Agreement, CHARAK and AG agree to provide, and RMTI
agrees to pay CHARAK and/or AG for, such reasonable technical and clinical
consultation and support at mutually convenient times during normal business
hours as RMTI may request, including the services of AG, which shall be
exclusive to RMTI with respect to all aspects of the Licensed Technology. AG's
services shall be billed, for the first year of this Agreement, at the rate of
US $1,500.00 per day, or US $187.50 per hour, and all other personnel will be
billed at mutually agreed-upon market rates. All costs and expenses will be
reimbursed promptly upon invoicing by CHARAK and/or AG.

         3.6 Audits. RMTI shall make its and its Affiliate(s) records pertaining
to the performance of this Agreement available to independent auditors
designated by and at the expense of CHARAK, at RMTI's facilities and at
reasonable and mutually convenient times during normal business hours, for audit
purposes and shall take any reasonable

                                                                    Page 7 of 20
<PAGE>

actions required to facilitate such audit. All information obtained during any
such audit shall be deemed confidential, and such auditors shall report only the
conclusion reached by their audit relative to accuracy and adequacy of payments
including Royalty payments made to CHARAK hereunder. No such audit shall be
conducted more frequently than once per year, or carry back more than two years.
It is however agreed that if as a result of any such audit it is found that RMTI
has knowingly not duly met its payment obligations to CHARAK then the cost of
such audit shall be borne by RMTI. RMTI shall include this same obligation in
any sublicenses it issues, except that the facilities involved shall be those of
each sublicensee, as determined most appropriate by them.

                                   ARTICLE IV
                          REPRESENTATIONS BY AND OTHER
                      UNDERTAKINGS BY CHARAK, AG. AND RMTI

         4.1 CHARAK for itself and all CHARAK Affiliates, and AG warrant to RMTI
that CHARAK is the sole and exclusive owner of the Licensed Technology as of the
date of execution hereof, subject only to the HFHS Shop Right, and that CHARAK
has the right to grant the license granted hereunder; that no agreement or other
document effective as of the date of execution hereof is in force which is in
conflict herewith and neither CHARAK or AG will execute any such agreement
during the active term hereof; that CHARAK officers have the full right,
authority and authorization to execute this Agreement and to grant the rights
granted to RMTI hereunder; and that no consent or authorization of any third
party is required as a condition precedent to its execution or performance of
this Agreement.

         4.2 RMTI hereby represents to CHARAK that no agreement or other
document in force as of the date hereof is in conflict herewith; that its
officers have the full right, authority and authorization to execute this
Agreement; and that no consent or authorization of any third party is required
as a condition precedent to its execution or performance of this Agreement.

         4.3 RMTI shall be responsible for and use its best efforts to make sure
that no Licensed Products will knowingly be sold or otherwise distributed by it
or its sublicenses/Affiliates that are not in full compliance with all legal and
regulatory requirements. RMTI assures CHARAK that the Licensed Products shall be
developed,

                                                                    Page 8 of 20
<PAGE>

manufactured, transported, stored, handled, packaged, marketed, promoted,
distributed, offered for sale and sold in accordance with all regulatory
authorities, including without limitation, the FDA, in any country of the
licensed territory, including, without limitation, cGCP, cGLP, cGMP regulations.
The Licensed Products shall not be adulterated or misbranded as defined by the
Federal Food, Drug and Cosmetic Act when delivered and shall not be a product
which would violate any section of such Act if introduced in interstate
commerce.

         4.4 AG and CHARAK shall promptly and diligently pursue a grant of
regulatory exclusivity ("Orphan Drug Status) from the US FDA for the Licensed
Products at their own expense in the name of RMTI.

                                    ARTICLE V
           INFORMATION AND OWNERSHIP REGARDING THE LICENSED TECHNOLOGY

         5.1 The Licensed Technology, (except for FDA-related rights, etc.) and
all inventions, improvements, enhancements and modifications thereto made,
conceived or developed by CHARAK or AG, or by any other person or entity
controlled or owned by either (all jointly and severally constituting the
"CHARAK Affiliates") after the date of this Agreement, and any patent covering
such inventions, improvements, enhancements, modifications in whole or part
which said CHARAK Affiliates now or hereafter own, control, or have the right to
commercially exploit, ("CHARAK Enhancements") shall remain the sole and
exclusive property of one or more of the CHARAK Affiliates but shall be deemed
included as elsewhere specified herein as within the license hereby granted.
CHARAK Affiliates shall, upon demand, execute and deliver to RMTI, or cause to
be executed and delivered to RMTI, such conventional documents as are deemed
reasonably necessary or advisable by counsel for RMTI for filing in the
appropriate public offices to evidence the grant of the exclusive license for
the Licensed Technology hereby granted to RMTI.

         5.2 CHARAK, AG and all CHARAK Affiliates expressly assure RMTI that
they believe that there is nothing that would invalidate/restrict their rights
in the Licensed Technology, except the HFHS Shop Right.

                                                                    Page 9 of 20
<PAGE>

         5.3 All inventions, improvements, enhancements and modifications to the
Licensed Technology made, conceived or developed solely by RMTI or its agents
and representatives without involvement of CHARAK, AG or any CHARAK Affiliates
after the date of this Agreement which absent a license would infringe Licensed
Patents, and any patent covering the same ("RMTI Enhancements"), shall be the
sole property of RMTI but may be used non-commercially by CHARAK during the
active term of this Agreement.

         5.4 All inventions which have at least one inventor which is either AG
             or a CHARAK Affiliate and at least one inventor which is neither AG
             nor a CHARAK Affiliate shall (as between RMTI and CHARAK) be
             assigned to CHARAK and RMTI jointly and shall be part of the
             Licensed Technology under this Agreement.

                                   ARTICLE VI
                   INFRINGEMENT, INDEMNIFICATION AND INSURANCE

         6.1 (i) RMTI and CHARAK shall each promptly inform the other in writing
of any alleged infringement or unauthorized use by a third party of Licensed
Technology of which it becomes aware and provide such other with any available
evidence of such unauthorized activity.

         6.2 RMTI shall have the right, but not the obligation to defend any and
all charges of infringement of intellectual property rights concerning the
manufacture, use, sale, offer for sale, or importation of the Licensed Products
whether such charge is made against RMTI, an RMTI Affiliate or sub-licensee or
CHARAK, or an Affiliate of CHARAK, or any combination thereof. RMTI shall also
have the right, but not the obligation to bring charges of infringement against
any other party on behalf of itself, its Affiliates or sub-licensee, and/or
CHARAK for infringement of the Patent Rights. In all such cases, RMTI shall have
the right, but not the obligation, to control such litigation or threatened
litigation, including the right to choose counsel, the right to direct the
conduct of the litigation, the right to settle or compromise the case or
position, and to take any other action as RMTI may, in its own discretion deem
appropriate. Upon request of RMTI, CHARAK agrees to permit RMTI to bring suit in
CHARAK's name and to join in such suit.

                                                                   Page 10 of 20
<PAGE>

         6.2.1 RMTI shall bear the expense for protecting the Patent Rights
during any infringement proceeding and shall receive the full benefit of any
recovery or settlement in connection with any such proceeding; provided,
however, that in the event CHARAK elects to participate in the expense of such
proceeding, any recovery and any expense relating to the protection of such
Patent Rights shall be shared by CHARAK and RMTI as follows:

                  (a) First, all expenses to be incurred by the parties in
                  protection of any Patent Rights and (including, without
                  limitation, attorney fees) shall be borne 85% by RMTI and 15%
                  by CHARAK and any recovery or award obtained shall first be
                  applied to reimburse RMTI and CHARAK in proportion to their
                  participation in such expenses;

                  (b) Any cash recovery other than a royalty remaining after the
                  reimbursement of RMTI and CHARAK of all such expenses shall be
                  distributed 85% to RMTI and 15% to CHARAK;

                  (c) If RMTI settles the litigation under terms requiring the
                  payment of a royalty to the infringer, RMTI shall bear 85% of
                  such payment and CHARAK shall bear 15% of such payment. The
                  amounts payable by CHARAK shall first be applied against the
                  royalties he is otherwise entitled to receive hereunder;

                  (d) In the event RMTI elects not to take any action against an
                  infringer of Patent Rights within ninety (90) days after
                  actual notice of infringement, CHARAK shall have the right,
                  but not the obligation, to do so and in which event CHARAK
                  shall be responsible for the costs of such litigation. In all
                  such cases CHARAK shall have the right to control such
                  litigation, including the right to choose counsel, the right
                  to direct the conduct of the litigation, the right to settle
                  or compromise the case and take any other action as CHARAK
                  may, in his discretion deem appropriate; provided, however,
                  that CHARAK may not grant a license or sublicense under the
                  Patent Rights to any third party for as long as the Patent
                  Rights are licensed exclusively to RMTI hereunder nor may
                  CHARAK enter into an agreement of any kind which would
                  interfere with, reduce or conflict with

                                                                   Page 11 of 20
<PAGE>

                  the rights granted to RMTI hereunder. RMTI shall not be
                  entitled to any recovery procured by CHARAK from such
                  protection of Patent Rights by way of settlement, judgment or
                  otherwise; provided, however, if RMTI elects to participate in
                  any such action before the suit is filed in court, the costs
                  shall be borne by and allocated between and recoveries shall
                  be distributed to CHARAK and RMTI mutatis mutandis in the same
                  manner as provided above except that 85% of the costs and
                  recoveries shall be borne by and distributed to CHARAK and 15%
                  of the costs and recoveries shall be borne by and distributed
                  to RMTI.

Notwithstanding the foregoing any infringement settlement that includes a
license for future sales of Licensed Products shall be regarded a sublicense and
shall be subject to the terms of this Agreement like any other sublicense.

         6.3.2 CHARAK Affiliates shall indemnify and hold harmless RMTI and its
Affiliates and their officers, directors and employees from and against any and
all Losses arising directly out of or resulting directly from any breach by
CHARAK or any of its Affiliates of any of its warranties, representations,
obligations or covenants contained herein.

         6.3.3 Neither party shall be liable, one to the other, for any
         indirect, special, punitive, consequential or exemplary damages arising
         out of or in connection with this Agreement.

         6.4 Insurance. RMTI agrees to purchase, at its sole cost, comprehensive
general liability insurance (occurrence or claims-made form) for bodily injury
and property damage, including contractual and product liability, in an amount
of not less than $3,000,000 combined single limits and provide CHARAK with a
certificate of insurance naming CHARAK as an additional insured. Such contract
of insurance shall be primary with respect of any other insurance available to
CHARAK and shall contain a waiver of subrogation by RMTI's insurance carrier
against CHARAK and its insurance carrier with respect to all obligations assumed
by RMTI pursuant to this Agreement. Such insurance shall contain provisions to
the effect that policy limits may not be reduced, terms changed, or the policy
cancelled without prior written consent from RMTI, and RMTI shall not give such
consent without first obtaining CHARAK's consent, which shall not be
unreasonably withheld.

                                                                   Page 12 of 20
<PAGE>

         6.5 Infringement. RMTI shall promptly confer and provide to one another
all available information pertaining to any and all charges and claims of
infringement that are made or brought against RMTI and/or CHARAK related to the
exercise of the license granted to RMTI pursuant to this Agreement, and RMTI
shall have the right but not the obligation to defend against such charges at
its own expense. CHARAK shall cooperate fully with such efforts. In any case or
instance where RMTI chooses not to defend any such infringement, RMTI shall duly
inform CHARAK in advance in writing, and shall provide relevant information then
known to RMTI in sufficient detail for CHARAK and/or its attorneys to understand
the merits and posture of the case. Upon such intimation CHARAK shall have the
right to defend such case and if CHARAK so chooses RMTI shall cooperate fully
with such efforts. The costs for the same shall be borne by the party carrying
on such defense and, in the event that CHARAK elects to defend the infringement,
any damage assessment in excess of what RMTI could have settled the case for, if
any, shall also be paid by CHARAK.

                                                                   Page 13 of 20
<PAGE>

         6.6      Indemnification.

                  6.6.1 RMTI shall indemnify and hold harmless CHARAK, AG and
                  their Affiliates and their officers, directors and employees
                  from and against any and all claims, losses, damages,
                  judgments, costs, awards, expenses (including reasonable
                  attorney's fees) and liabilities of every kind (collectively,
                  "Losses") arising directly out of or resulting directly from
                  any breach by RMTI of any of its warranties, guarantees,
                  representations, obligations or covenants contained herein.
                  "Affiliate" shall mean any corporation or partnership or other
                  entity, which directly or indirectly controls, is controlled
                  by, or is under common control with CHARAK and/or Dr. Gupta.
                  "Control" shall mean the legal power to direct or cause the
                  direction of the general management or partners of such entity
                  whether through the ownership of voting securities, by
                  contract or otherwise.

                                   ARTICLE VII
                                   TERMINATION

         7.1      This Agreement may be terminated as follows:

                  7.1.1 At the sole option of CHARAK and upon written notice by
                  CHARAK, in the event RMTI fails to meet any of its financial
                  obligations under this Agreement, but RMTI will have
                  forty-five (45) days following receipt of notice to cure the
                  violation.

                  7.1.2 At the option of either party and upon sixty (60) days
                  written notice, in the event of the other party's failure to
                  perform any of its non-financial duties or obligations under
                  this Agreement, but the defaulting party may cure and nullify
                  the violation during the notified period following receipt of
                  notice.

                  7.1.3 At the option of RMTI, at any time during the term
                  hereof with respect to any country, upon six (6) months
                  written notice.

                                                                   Page 14 of 20
<PAGE>

                  7.1.4    a. At the option of CHARAK, in the event RMTI shall
                  at any time be insolvent or shall have had a petition in
                  bankruptcy filed by or against it, provided, however, that
                  such petition is not dismissed within 120 days of the filing
                  thereof. For purposes of this agreement, "insolvent" shall
                  mean a party is unable to pay its debts as such debts mature.

                           b. In any particular country in which exclusivity due
                  to Patent Rights or regulatory action exists, in the event
                  RMTI fails to apply for Marketing Authorization within twelve
                  (12) months after successful completion of Phase III or
                  equivalent Clinical Studies needed for regulatory approval
                  (the "Target Date") unless such failure or delay is due to
                  events or circumstances beyond the reasonable control of RMTI.

         7.2 Remedies hereunder are not exclusive. The non-breaching party shall
         have all remedies available at law or in equity. The provisions of
         Article VIII and the obligations for payment of Royalties under Section
         3.3, so long as there is a Revenue Advantage as per Section 3.3, and
         RMTI obligations to CHARAK for any due and accrued License fees and/or
         other payments to CHARAK shall survive any termination of this
         Agreement.

         7.3 Upon termination of this Agreement, any sublicenses granted
         pursuant to this Agreement by RMTI shall also stand terminated
         simultaneously, but subject to same survival of obligations after
         termination as contained in Section 7.2 above being applicable to such
         sub-licensee(s), unless CHARAK agrees in writing to the continuance of
         any sub-license(s) on such terms and conditions as CHARAK may decide
         for such continuation.

                                  ARTICLE VIII
                                 CONFIDENTIALITY

         8.1 Definition of Confidential Information. As used in this Agreement,
"Confidential Information" shall mean all information which is transmitted in
written, graphic or photographic form and marked as "Confidential" or
transmitted in oral form and reasonably known to be confidential or claimed to
be so by the discloser at the time of transmittal or before any non-confidential
disclosure of it by the recipient, but Confidential

                                                                   Page 15 of 20
<PAGE>

Information does not include that which (a) can be shown by the receiving party
to have been in its possession prior to disclosure to it by the transmitting
party; (b) at the time of disclosure hereunder is, or thereafter becomes,
through no fault of the receiving party, part of the public domain by
publication or otherwise; or (c) is furnished to the receiving party by a third
party after the time of disclosure hereunder as a matter of right, who owes no
obligation of confidentiality to the transmitting party with respect to the
Confidential Information.

         8.2 Exchange of Information. All Confidential Information exchanged
between CHARAK and RMTI pursuant to this Agreement or previously exchanged
between CHARAK and RMTI relating to the subject matter hereof, shall be kept
confidential by each party with the same degree of care normally accorded by
such party to its own confidential information except for purposes authorized by
this Agreement. Neither party shall disclose such Confidential Information to
any person or entity during the term of this Agreement and for a period of five
(5) years after the termination of this Agreement, unless previously authorized
in writing by the other party; provided, however, that each party may disclose
said Confidential Information to responsible officers (including authorized
representatives) and employees of any party who requires said information for
the purposes contemplated by this Agreement, provided that said officers and
employees shall have assumed like obligations of confidentiality.

                                   ARTICLE IX
                                  ASSIGNABILITY

                  9.1 Notwithstanding the references in this Agreement to
         non-transferability of the license contained herein, (i) CHARAK shall
         be permitted to assign its rights and obligations under this Agreement
         to a third party purchaser of all or substantially all of CHARAK 's
         business pertaining directly to the Licensed Technology, and (ii) RMTI
         shall be permitted to assign its rights and obligations under this
         Agreement to a third party purchaser of all or substantially all of
         RMTI's business pertaining directly to sale or use of the Licensed
         Products, but only by an express undertaking by the purchasers to
         faithfully uphold and perform all of RMTI's duties and obligations
         hereunder, which shall not be divided or fractionalized by any such
         assignment. This Agreement shall be binding upon and

                                                                   Page 16 of 20
<PAGE>

         shall inure to the benefit of CHARAK and RMTI and their permitted
         assigns and successors in interest.

                                    ARTICLE X
                                  GOVERNING LAW

         10.1 This Agreement shall be governed by and construed in accordance
with the laws of the State of Michigan and the Federal laws relating to patents,
with jurisdiction in the State of Michigan.

                                   ARTICLE XI
                                     NOTICES

         11.1 For purposes of notices given pursuant to this Agreement, the
addresses as set forth in Section 11.2 shall be used unless changed by written
notice given by one party to the other:

         11.2 For the purposes of notices under Section 11.1 above, the
following addresses shall be used:

         For AG:  Ajay Gupta, MD

         For CHARAK:       Charak LLC
                           2336 Hickory Pointe Drive
                           Ann Arbor, MI 48105

                           Attn.:  Ajay Gupta, President and CEO
                           Facsimile Number:  323 563 4924

         For RMTI:         Rockwell Medical Technologies, Inc.
                           30142 Wixom Road
                           Wixom, MI 48393
                           Attn.:  Rob Chioini, Chairman, President, and CEO
                           Facsimile Number:  (248) 960-9119

         11.3 All notices hereunder shall be in writing and shall be deemed
given when (a) personally delivered; or (b) when received, if mailed by
certified mail, return receipt requested, postage prepaid; or (c) when received
when sent by courier service, UPS, or

                                                                   Page 17 of 20
<PAGE>

equivalent carrier; or (d) on the first business day after receipt of facsimile
copy when transmitted by confirmed facsimile, with hard copy mailed by United
States mail.

                                   ARTICLE XII
                                  MISCELLANEOUS

         12.1. Headings. The headings used in this Agreement are for purposes of
convenience and ready referral and shall not be deemed to limit or expand the
construction of any paragraph to which they appertain.

         12.2 Severability. The invalidity or unenforceability of any provision
of this Agreement shall not affect or limit the validity or enforceability of
any other provision hereof.

         12.3 No Waiver. No waiver by either party or any breach of the terms of
this Agreement shall be deemed a waiver of any subsequent breach thereof.

         12.4 Entire Understanding. This Agreement embodies the entire
understanding and agreement between the parties and supersedes all previous
negotiations, representations and writings, written or oral, with respect to the
subject matter hereof. This Agreement may be amended or modified only by an
instrument in writing, duly signed by the parties hereto.

         12.5 This agreement may be executed in more than one counterpart, each
of which shall be deemed an original document, and all of which taken together
shall be one and the same Agreement.

         12.6 Dr. Ajay Gupta assures RMTI and warrants that CHARAK is and will
remain fully capable of performing all of its obligations under this Agreement,
that all statements and verifications of CHARAK and AG herein are believed in
good faith to be true, and that AG will faithfully and satisfactorily provide
all services and information required of him by this Agreement. RMTI assures
CHARAK and AG that RMTI has full corporate power and authority to enter into
this Agreement, consummate the transactions contemplated herein and perform its
obligations hereunder and RMTI shall faithfully and satisfactorily perform its
obligations as required of it by this Agreement.

                                                                   Page 18 of 20
<PAGE>

         12.7 Force Majeure - If either CHARAK /AG or RMTI shall be prevented by
fire, war, civil disturbances, acts of God, intervention of a Government
Authority, or other similar events beyond the reasonable control of CHARAK/AG or
RMTI from performing their respective obligations hereunder, neither CHARAK/AG
nor RMTI shall be liable to the other for damages ("Force Majeure"). The party
being able to perform may, at its sole option, extend the duration for the
performance of the obligations by the other under this Agreement by a term equal
in length to the period during which the other party was unable to perform its
obligations hereunder on account of Force Majeure, or waive such obligations.

                 12.8 Independent Contractor --CHARAK/AG's relationship with
RMTI under this Agreement shall be that of independent contractor. Nothing in
this Agreement shall be deemed or construed by the parties hereto or by any
third parties creating the relationship of principal and agent, employer and
employee or of partnership or of joint venture between the parties hereto.

                                                                   Page 19 of 20
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year first above written.

ATTEST:                             CHARAK LLC

                                    By: /s/ Dr. Ajay Gupta
----------------------------            ---------------------------
                                         Dr. Ajay Gupta
                                         President and CEO

ATTEST:                             ROCKWELL MEDICAL TECHNOLOGIES, INC.

                                    By: /s/ Robert Chioini
----------------------------            ---------------------------
                                         Robert Chioini
                                         Chairman, President, CEO

ATTEST:                             DR. AJAY GUPTA

                                    By: /s/ Dr. Ajay Gupta
----------------------------            ---------------------------

                                                                   Page 20 of 20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}]]